Datapoint: FDA Approves Aurinia’s Lupus Drug

The FDA last week approved Aurinia Pharma’s Lupkynis for the treatment of lupus nephritis, an inflammation of the kidneys in lupus patients that can lead to renal failure. This is the FDA’s second lupus nephritis approval in recent months. GlaxoSmithKline’s more broad lupus therapy Benlysta in December scored the first-in-class nod, and currently holds preferred status, with utilization management restrictions, for 15% of all covered lives under the pharmacy benefit.

SOURCE: MMIT Analytics, as of 1/25/21

0

0

0 Comments

0

0

• Datapoint